Immatics to Receive $120M Upfront for Moderna Collaboration

Immatics (Nasdaq: IMTX) and Moderna (Nasdaq: MRNA) will collaborate to develop innovative and transformative oncology therapies for cancer patients with high unmet medical need.

The strategic research and development partnership will see Immatics receive an upfront payment of $120 million. The company will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments that could exceed $1.7 billion.

Toni Weinschenk, PhD, Chief Innovation Officer at Immatics, said, “We are thrilled to join forces with Moderna in our quest to pioneer innovative and transformative therapies to combat cancer.”


This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics’ T cell-redirecting (TCR) platform with Moderna’s cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.

Moderna will lead the clinical development and commercialization of cancer vaccines and therapeutics resulting from the collaboration.

Rose Loughlin, Ph.D., Moderna’s Senior Vice President for Research and Early Development, said, “This partnership presents a groundbreaking opportunity to leverage our mRNA technology alongside Immatics’ TCR platform, potentially diversifying and augmenting the way we approach cancer treatment. We believe this collaboration will accelerate the development of novel oncology therapies and bring us one step closer to providing significant benefits for patients with high unmet medical needs.”

About Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immune-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases.

Moderna Genomics was created to leverage the recent advancement in both the RNA delivery platform and the genomic medicines to create the next generation of in vivo gene editing therapeutics. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit

Share This Article


About the Author

Immatics to Receive $120M Upfront for Moderna Collaboration

Catie Corcoran

Biotech Editor